Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Leases: 2023-2025

Historic Current Leases for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Mar 2025 value amounting to $61,229.

  • China SXT Pharmaceuticals' Current Leases fell 0.11% to -$34,776 in Q3 2025 from the same period last year, while for Sep 2025 it was -$34,776, marking a year-over-year decrease of 0.11%. This contributed to the annual value of $61,229 for FY2025, which is 5.01% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Current Leases stood at $61,229 for FY2025, which was up 5.01% from $58,310 recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Current Leases ranged from a high of $61,229 in FY2025 and a low of $58,089 during FY2023.
  • In the last 3 years, China SXT Pharmaceuticals' Current Leases had a median value of $58,310 in 2024 and averaged $59,209.
  • Data for China SXT Pharmaceuticals' Current Leases shows a peak YoY climbed of 5.01% (in 2025) over the last 5 years.
  • Yearly analysis of 3 years shows China SXT Pharmaceuticals' Current Leases stood at $58,089 in 2023, then rose by 0.38% to $58,310 in 2024, then climbed by 5.01% to $61,229 in 2025.